NCT00508690

Brief Summary

The purpose of this study is to determine optimal prophylactic antibiotics administration method in elective laparoscopic colorectal surgery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
584

participants targeted

Target at P75+ for phase_3

Timeline
Completed

Started Sep 2007

Typical duration for phase_3

Geographic Reach
1 country

5 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 27, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 30, 2007

Completed
1 month until next milestone

Study Start

First participant enrolled

September 1, 2007

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2011

Completed
Last Updated

September 19, 2012

Status Verified

September 1, 2012

Enrollment Period

4.3 years

First QC Date

July 27, 2007

Last Update Submit

September 18, 2012

Conditions

Keywords

Antibiotic ProphylaxisColorectal SurgeryLaparoscopy

Outcome Measures

Primary Outcomes (1)

  • Incidence and classification of surgical site infection (SSI)

    Within the first 30 days after surgery

Secondary Outcomes (1)

  • Incidence of colitis, other infectious diseases and other postoperative complications.

    Within the first 30 days after surgery

Study Arms (2)

IV

ACTIVE COMPARATOR

Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery

Drug: cefmetazole

Oral/IV

ACTIVE COMPARATOR

2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery

Drug: kanamycin/metronidazole

Interventions

Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery

IV

2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery

Oral/IV

Eligibility Criteria

Age20 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Colorectal tumor(cancer, adenoma and suspected cases) with planned elective laparoscopic colorectal resection

You may not qualify if:

  • ECOG Performance Status \>=2
  • Age\<20
  • Any organ dysfunction
  • Ileus
  • Preoperative infectious disease
  • Antibiotic administration before surgery
  • Steroid administration before surgery
  • Neo-adjuvant radiation and/or chemo therapy
  • Severe diabetes mellitus
  • Pregnancy/lactational woman
  • Severe allergy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (5)

Kyoto Univercity Hospital

Kyoto, Kyoto, 606-8507, Japan

Location

National Hospital Organization, Kyoto Medical Center

Kyoto, Kyoto, 612-8555, Japan

Location

Kyoto Katsura Hospital

Kyoto, Kyoto, 6158256, Japan

Location

Tenriyorozu Hospital

Tenri, Nara, 6328552, Japan

Location

Kitano Hospital

Osaka, Osaka, 5308480, Japan

Location

Related Links

MeSH Terms

Conditions

Colorectal Neoplasms

Interventions

CefmetazoleKanamycinMetronidazole

Condition Hierarchy (Ancestors)

Intestinal NeoplasmsGastrointestinal NeoplasmsDigestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal DiseasesColonic DiseasesIntestinal DiseasesRectal Diseases

Intervention Hierarchy (Ancestors)

CephamycinsCephalosporinsbeta-LactamsLactamsAmidesOrganic ChemicalsThiazinesSulfur CompoundsHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic CompoundsAminoglycosidesGlycosidesCarbohydratesNitroimidazolesNitro CompoundsImidazolesAzolesHeterocyclic Compounds, 1-Ring

Study Officials

  • Hiroaki Hata, MD

    National Hospital Organization Kyoto Medical Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
member

Study Record Dates

First Submitted

July 27, 2007

First Posted

July 30, 2007

Study Start

September 1, 2007

Primary Completion

December 1, 2011

Study Completion

December 1, 2011

Last Updated

September 19, 2012

Record last verified: 2012-09

Locations